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Abstract
Within the large group of Estrogen Receptor alpha (ERa)-negative breast cancer patients, there is a subgroup carrying the
phenotype ERa
2,P R
2, and Her2
2, named accordingly ‘‘Triple-Negative’’ (TN). Using cell lines derived from this TN group, we
wished to establish cell clones, in which ERa is ectopically expressed, forming part of a synthetic lethality screening system.
Initially, we generated cell transfectants expressing a mono-cistronic ERa transcription unit, adjacent to a separate dominant
selectable marker transcription unit. However, the yield of ERa expressing colonies was rather low (5–12.5%), and only about
half of these displayed stable ectopic ERa expression over time. Generation and maintenance of such cell clones under
minimal exposure to the ERa ligand, did not improve yield or expression stability. Indeed, other groups have also reported
grave difficulties in obtaining ectopic expression of ERa in ERa-deficient breast carcinoma cells. We therefore switched to
transfecting these cell lines with pERa-IRES, a plasmid vector encoding a bicistronic translation mRNA template: ERa Open
Reading Frame (ORF) being upstream followed by a dominant-positive selectable marker (hygro
R) ORF, directed for
translation from an Internal Ribosome Entry Site (IRES). Through usage of this bicistronic vector linkage system, it was
possible to generate a very high yield of ERa expressing cell clones (50–100%). The stability over time of these clones was
also somewhat improved, though variations between individual cell clones were evident. Our successful experience with
ERa in this system may serve as a paradigm for other genes where ectopic expression meets similar hardships.
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Introduction
Tumor expression of estrogen receptor alpha (ERa) plays an
important role in the clinical care of breast cancer patients both as a
prognostic factor and as a therapeutic target. Unfortunately, about
two-thirds of breast cancer patients have an estrogen receptor
alpha-negative disease. Within this large group of ERa
2negative/
endocrine therapy-resistant breast cancer patients, the Triple-
Negative (TN) subgroup has bad prognosis, as it tends to develop
metastases. So far, this group is being treated by surgery/irradiation
and for the most part nonspecific chemotherapy [1].
Genes, whose activity, expression or dependence is considered
to have increased in cancer, are prime candidates for therapeutic
intervention. Cancer cells may depend upon such changes in gene
expression, not only during tumor initiation, but also during
malignancy progression (i.e. ‘‘oncogene addiction’’). This is
exemplified by the choice of the oncogene ERBB2/HER2 as
drug target in ERBB2/HER2-positive breast cancer [2]. Alterna-
tively, using the concept of synthetic lethality [3], efforts have been
directed towards identification of chemicals/drugs or target genes
whose activation or ablation, respectively, synergizes with
mutations in either oncogenes or tumor suppressor genes [4,5].
The availability of large-scale synthetic low-molecular-weight
chemical libraries has allowed high-throughput-screening (HTS)
for compounds that are synergistically lethal with defined human
cancer aberrations in activated oncogenes or tumor suppressor
genes; the so called ‘‘chemical synthetic lethality screens’’. The
generation of human/mouse genome-wide siRNAs and shRNA-
expressing libraries has significantly advanced the complementing
approach of ‘‘genetic synthetic lethality screen’’. The latter is being
performed either at the single gene level, in an array format, or
primarily by retroviral/lentiviral-pools carrying shRNA expression
cassettes that are used to infect target cells at low multiplicity of
infection [6,7]. In the case of the Triple-Negative derived
BRCA1/BRCA2-deficient breast cancers, poly(ADP-ribose) poly-
merase (PARP), with or without DNA damaging agents, is
synthetic lethal with BRCA1- or BRCA2-deficiency [8,9].
Likewise, the frequent inactivation of the PTPN12 tyrosine
phosphatase tumor suppressor gene in TN derived tumors renders
them sensitive to inhibitors of multiple tyrosine kinases [10].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31977The first system toward which our groups have decided to apply
the synthetic lethality screening approach entails ERa-negative
breast carcinoma TN-derived cultured cells. In order to do so, one
needs to test the specificity of the identified targets in an in vitro cell
culture system. A compulsory control ingredient of the synthetic
lethality screening in the ERa-deficient TN breast carcinoma cell
lines is stable transfectants expressing the human ERa cDNA. In
view of the heterogeneity observed in the TN breast cancer group,
it is essential to generate such complemented systems in several
different TN-derived cell lines.
In light of the difficulty in creating stable expression of ERa (see
below), this manuscript offers an alternative methodology [11,12]
of doing so with greater success and fidelity. The generated ERa
expressing clones can serve for the long term study of a variety of
ERa associated topics.
Methods
A. Plasmids and constructs
pCDNA3-ERa, was constructed by the late Dr. Arnold Simons
by first subcloning a 1820 bp SalI fragment encoding the complete
coding sequence of wild type hERa from the GAL4 DB-hER
plasmid [13] into the pBluescript II SK
2 plasmid. Then the XhoI
- HindIII fragment encoding the ERa sequence from BlueScript
was cloned into the pCDNA3.3 a neo expression vector from
Invitrogen. pCDNA3 by itself was named pCDNA3-empty, and
used to construct the G418 resistant ERa non-complemented cell
clones. The neo
R coding region is driven by the SV40 early genes
promoter.
The pIRES-ERa plasmid (Fig. 1) is a derivative of the
pIREShyg3 bicistronic vector (Clontech). The expression cassette
of this vector contains the human cytomegalovirus (CMV) major
immediate early gene promoter, followed by multiple cloning sites
for cDNA/coding region insertion. A synthetic intron, is included
downstream of the multiple cloning site. The encephalomyocar-
ditis virus (EMCV) Internal Ribosome Entry Site (IRES) is
followed by the bacterial hygromycin B resistance gene (Hygro
R)
and the SV40 polyadenylation signal. The coding sequence of the
human ERa-cDNA was cloned downstream of the CMV
promoter into the EcoRV site of PIREShyg3, as a blunted
EcoRV-XhoI fragment.
The pCMV-Bam-ERa-Hygro was constructed first by deleting
the BamHI fragment encoding CD20 from pCMV-CD20 and
religation of the vector. Next, an XbaI- HindIII fragment encoding
TK-neo from the pCMV-Bam-neo was replaced with an NruI-SalI
fragment encoding for TK-hygro
R cassette from pCEP4 (Invitro-
gen). The coding sequence of human cDNA ERa was then cloned
into pCMV Bam-Hygro by cloning an EcoRV-XhoI blunt-ended
fragment encoding human ERa from pCDNA3-ERa (see above),
into the BamHI site of pCMV-Bam-Hygro.
The firefly luciferase reporter plasmid p2xERE-pS2-luc [14] was
a kind gift from Prof. Y. Sharoni (Ben Gurion University) and the
normalizing renilla pRNL-TK-luc (Promega) was a kind gift from
Prof. L. Vardimon (Tel Aviv University).
B. Cells growth
MDA-MB-231 [15] and GILM2 [16] were a kind gift from
Prof. J. Price, MD Anderson. MDA-MB-435 and BT549 breast
carcinoma cell lines were purchased from ATCC. MCF7 (ATCC)
was a kind gift from R. Pinkas-Kramarski. Cell lines were routinely
cultured at 37uC, 5% CO2, in DMEM supplemented with 5%
fetal bovine serum (FBS), 4 mM L-glutamine, and penicillin/
streptomycin; these five medium ingredients were purchased from
Biological Industries (Israel). ERa transfected cell clones were
maintained in phenol red-free DMEM medium (Biological
Industries, Israel) supplemented with 5% dextran coated Charcoal
Stripped fetal calf Serum (CSS, manufactured by Hyclone, US) to
prevent ERa activation (see below).
C. Cell transfection and clonal selection
MDA-MB-231, MDA-MB-435, and GILM2 transient and
stable transfections were carried out using jetPEI reagent (PolyPlus
Transfection, France) according to the manufacturer’s instruc-
tions. In order to produce stable clones, a 1:5–1:20 dilutions of
5610
6 transfected cells was performed into 100 mm Petri dishes
48 hours post transfection. Selection was commenced the day
after. Selective media consisted of DMEM without phenol-red,
supplemented with 5% dextran charcoal fetal bovine serum (FBS),
4 mM L-glutamine, antibiotics (10 units/ml of penicillin and
50 mg/ml streptomycin) and the selective drug. Selection of stable
clones was performed at 0.4 mg/ml G418 (Calbiochem) for
pCDNA3-neo based clones, or at 0.2 mg/ml Hygromycin B (A.G.
Scientific) for pIREShyg3 and pCMV-Bam-ERa-Hygro
R based
clones. Selective media was refreshed every 3 days thereafter.
When colonies were big enough and interspaced, they were
transferred to 48- well cell culture plates. For long term
maintenance, 0.2 mg/ml G418, or 0.1 mg/ml Hygromycin B
were used.
D. Western blot analysis
MCF7, BT549, MDA-MB-231, MDA-MB-435, GIML2 and
their clonal derivatives were washed twice with cold Hanks buffer
(Biological Industries, Israel), scraped with a rubber policeman and
collected to a new tube. The cells were then centrifuged at
2000 rpm, 4uC for 5 minutes and pellets were lysed in ice-cold
modified RIPA buffer (1% NP-40, 50 mM Tris pH 8, 0.15 M
NaCl, 5 mM EDTA, 0.5% DOC and 1 mM PMSF, without
SDS). Lysates were incubated on ice for 10 minutes, then cleared
by centrifugation and stored in 270uC until use. For the Western
blot analysis, the protein of each cell lysate was quantified by using
the Bradford assay. 50 mg of each lysate was diluted 1:2 with a 46
SDS-PAGE sample buffer to a final concentration of 26 SDS-
PAGE sample buffer (0.12 M Tris-Cl pH 6.8, 4% SDS, 20%
glycerol, 0.2 M DTT, 0.008% bromophenol blue). These lysates
were denaturated and separated on 10% polyacrylamide gel at
100v for 90 minutes at room temperature. Proteins were
transferred to nitrocellulose membranes (BioScience, Germany)
by electroblotting for 120 minutes at 12–20v or 120–150 mA.
Membranes were blocked with blocking solution- 1% nonfat dry
milk in PBS-T (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4
containing 0.1% tween) 20 for 1 hour at room temperature. The
membranes were then probed with hERa mouse monoclonal
primary antibody (NCL-ER-6F11; Novocastra Labs Ltd, England)
at 1:1000 dilution in blocking solution overnight at 4uC, followed
by 365 min washes in PBS-T 0.1%. Next, the membranes were
incubated for 1 hour at room temperature with Goat anti mouse
IgG HRP conjugated secondary antibody (Sigma, Israel), at
1:5000 dilution in blocking solution. Next, 365 min washes were
preformed and the membranes were incubated with a home-made
Figure 1. Map of pIRES-ERa bicistronic plasmid. The vector
contains a single mammalian transcription unit initiating from the CMV
immediate early promoter and terminating with an SV40 derived polyA
addition fragment.
doi:10.1371/journal.pone.0031977.g001
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1.25 mM luminol, 0.2 mM p-cumaric acid, 0.01% H2O2) for
1 minute. Blots were then exposed to film (Kodak) and developed.
Signal quantization was performed by densitomentric analysis using
a GE ImageQuant 350 scanner. After antibody stripping, a-tubulin
was probed with a mouse monoclonal antibody (Sigma, Israel) at a
dilution of 1:5000 and used as a cellular normalizing marker.
E. Dual-luciferase reporter assay
In order to assay ERa activity, cells were seeded in 24-well cell
culture plates at 50–70% density, in DMEM supplemented with
5% FCS. The next day, the cells were transiently co-transfected
with 0.5 mg p2xERE-PS2-luc (primary reporter vector containing
the firefly luciferase gene under the ERa Response Element; i.e.
ERE) and 0.3 mg pRNL-TK-luc (secondary reporter vector
containing the Renilla luciferase gene under the constitutive HSV
TK promoter), using the jetPEI transfection reagent. Forty-eight
hours post-transfection, cells were washed twice with Hanks’
(Biological industries), a balanced salts solution without phenol
red, and cell lysates were prepared as described in the
manufacturer’s protocol for dual-luciferase reporter assay (Pro-
mega, USA). Briefly, cells were lysed with 45 mL/well of Passive
Lysis Buffer for 10 minutes at room temperature. The firefly
luciferase assay was initiated by adding 5–15 mL aliquot of cell
lysate to 50 mL of Luciferase Assay Reagent II (LAR II). After
recording the luminescence, 50 mL of Stop & Glo reagent was
added to the same tube in order to quench the firefly luciferase
reaction and simultaneously activate the Renilla luciferase reaction.
Firefly and Renilla luciferase activities were measured using a LKB
Wallac 1250 Luminometer. The firefly luciferase luminescence
measured was proportional to the amount of active ERa protein
present in the cells. The Renilla luciferase luminescence was
proportional to the efficiency of the transfection. This internal
control provides a convenient and reliable assay of efficiency.
Normalized luciferase luminescence was calculated as followed:
[(firefly luciferase activity/Renilla luciferase activity)6100]. These
results, determined from lysates ERa complemented clones (as
well as the positive and negative control), were then normalized
again to MCF-7 positive control by dividing them to the same
ratio obtained from the positive control: [(firefly/Renilla lumines-
cence6100)/(MCF-7 firefly/Renilla luminescence6100)6100]. All
experiments were performed several times in duplicates.
F. RT-PCR
For expression confirmation originating from the pIRES-ERa
construct, RT-PCR was conducted. Two mg of total RNA
extracted using EZ-RNA isolation kit (Biological Industries, Israel)
were transcribed into first strand cDNA by hexamer priming,
followed by PCR reactions as specified in the Long range RT-
PCR kit (Qiagen). The PCR conditions included preincubation for
3 minutes at 93uC and 40 cycles comprised of 30 seconds at 93uC,
30 seconds at 54uC, 4.5 minutes at 68uC, and finishing up
10 minutes at 68uC.
PCR primers (Hylabs, Israel) were as follows:
ERa:
Sense 59-ATGACCATGACCCTCCACAC-39,
antisense 59-AGACTGTGGCAGGGAAACC-39
Hygromycin B:
sense 59- CTGTCGAGAAGTTTCTGATCG-39
antisense 59- AGTACTTCTACACAGCCATCG-39
G. Estimation of the cell growth doubling time
Each clone was seeded at a density of 2.5–3610
4 cells in 24-well
tissue culture plates, and was incubated at 37uCi n5 %C O 2. The
cells were counted every day for 5–6 days, using a cell counting
chamber (Hemocytometer). The doubling time of each clone was
calculated as following: [2624 hours/(Ave (no. of cells in day
(X+1)/no. of cells in day X)].
Results
A. Generation & characterization of ERa-expressing MDA-
MB-231 stable transfectants with the pCDNA3-Era
expression vector
A1. Transfection and selection of ERa expressing clones
in MDA-MB-231 cells. In order to establish a supporting
control system for synthetic lethality screening of ERa-negative
breast cancer cells (of the TN subgroup), two human epithelial
breast carcinoma cell lines, BT549 and MDA-MB-231, were
initially utilized as recipients for the ERa-expressing constructs.
The MDA-MB-231 cell line was particularly suitable for such
preliminary studies since it is highly aggressive both in vitro as cell
culture and in vivo upon grafting [15].
These two cell lines were initially transfected with pCDNA3-
ERa. Simultaneously, these cell lines were also stably transfected
with the pCDNA3 vector by itself, to serve as a negative control
(pCDNA3-empty). Subsequent selection with G418 resulted in the
establishment of the two groups of stable cell clones, ERa-
complemented and ERa-empty (non-complemented). Initial
studies performed in the presence of DMEM medium supple-
mented with 5% FCS showed that similar to other groups [17,18],
the ERa complemented clones were much harder to establish than
the empty vector control group. This observation was also
reminiscent of studies demonstrating that ERa expression
following long-term estrogen deprivation in ERa-positive breast
cancer cells is thereafter manifested by an initial phase of estrogen
hypersensitivity. This phase is characterized by apoptosis and
rapid tumor regression at concentrations of estrogen (E2, Sigma
Israel) below 10
213 M [19].
For these reasons, we decided to attempt generating the ERa-
complemented MDA-MB-231 clones (which in some way are
analogous to E2 deprived ERa positive cells) in DMEM without
phenol red, supplemented with 5% CSS. This way, exposure to
residual ERa-receptor-activating agents was minimized, making
the clones less sensitive to the ectopic expression of ERa.
In order to examine whether estrogen deprivation affects the
stability and long term expression of functional ERa, newly
emerging clones were grown simultaneously in e the regular
phenol red-free DMEM supplemented with 5% CSS, as well as in
DMEM supplemented with 5% FCS.
Forty established MDA-MB-231 cell clones selected for G418
resistance were then tested for ERa expression by Western blot
analysis. Fig. 2 shows that only few clones (ERa-2, ERa-7a, ERa-
8a and ERa-17a) of the established cell clones, express the protein.
MCF7, a bona fide ERa-positive cell line, was used as positive
control. ERa-16a, a cell clone which was established after
transfection with pCDNA3-ERa integrating plasmid, turned out
not to express the protein. It also served us as a negative control,
when required. The four clones show various levels of ERa
expression, as compared to the positive control (Fig. 2).
A2. Selecting for ERa-active clones. The next phase was to
analyze whether the selected clones synthesizing the ERa, protein
express a functional receptor. The quantification of ERa activity
was performed by the dual luciferase reporter assay (see Methods).
MDA-MB-231 established clones were initially tested while
grown in DMEM supplemented with 5% FCS, which naturally
contains estrogen (E2).
ER-Alpha-cDNA as Part of a Bicistronic Transcript
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MB-231 established clones. Four clones; 231-ERa-2, 231-ERa-7a,
231-ERa-8a and 231-ERa-17a, exhibited 66% to 111% of the
expression level displayed by the positive control MCF7. Five
clones; 231-ERa-3, 231-ERa-6a, 231-ERa-11a, 231-ERa-16a
and 231-ERa-20, expressed between 0% and 30% receptor
activity, as compared to MCF7. Not only were these levels very
low, but further ERa reporter assays showed that these five clones
continued loosing activity over time. Additional tests performed on
the former four ERa expressing clones, showed maintenance of
appreciable levels of activity despite fluctuations over time (see
below).
A3. Responsiveness to ligand. The next step was to
determine whether the ectopically expressed ERa was under
hormonal regulation. Several studies have shown that adding
estrogen to serum starved ERa -positive cells, or to ERa
ectopically expressed cells, can down-regulate expression of the
receptor. The decrease requires a functional receptor and occurs
at both the protein and mRNA levels [19,20]. This phenomenon
has led us to systematically examine our ERa-complemented
clones for responsiveness to regulation by estrogen. In order to do
so, MCF-7 cells and four ERa complemented clones; 231-ERa-2,
231-ERa-7a, 231-ERa-8a and 231-ERa-17a, were seeded in
60 mm dishes under three different growth conditions: DMEM
supplemented with 5% FCS, phenol red-free DMEM
supplemented with 5% dextran coated charcoal filtered FCS
(Dex), and phenol red-free DMEM supplemented with 5%
dextran coated charcoal filtered FCS and 2610
28 ME 2. After
24 hours, expression of ERa in these clones, under the three
conditions was determined by Western immunoblot analysis.
Fig. 4. reveals that all dishes treated with E2 expressed a lower
level of ERa compared with the parallel estrogen starved cells
(Dex). As also expected, dishes treated with 5% FCS (FCS)
expressed a lower level of estrogen receptor compared to the Dex
cells, in accordance with estrogen saturating levels found in FCS.
Cell clones responding to the ligand regulation were also
assayed for receptor activity under the different treatments. In
order to do so, MDA-MB-231 established clones were seeded in
24-well tissue culture plates at the three different growth medium
conditions, as mentioned above. Luciferase reporter plasmids were
then transfected. After 24 hours, cell extracts were prepared and
assayed. Fig. 5 summarizes the results obtained from these clones,
comparing them to the positive control MCF7, grown in FCS.
When cell clones were seeded in DMEM supplemented with
5% FCS, they exhibited expression levels of 35% to 85% as
compared to the expression of the positive control MCF7, which
was assigned 100% relative activity. When cells were seeded in
phenol red-free DMEM supplemented with 5% CSS, they
behaved similarly to MCF7 and manifested an insignificant level
of active ERa, in line with absence of the ligand (E2). Naturally,
the receptor was not activated, leading to its inability to bind to the
ERE in p2xERE-pS2-luc reporter. However, when cells were
seeded in phenol red-free DMEM supplemented with 5% CSS
treated with 2610
28 M added E2, a significant increase in the
activity level was exhibited.
Obviously, MDA-MB-231 parental cell-line did not display any
significant expression level under all three conditions, since there is
no ERa to be activated in the first place.
A4. Stability of the cell clones. In order to determine the
clones’ stability over time, ERa activity was assayed periodically
Figure 2. pCDNA3-ERa transfectants of MDA-MB-231: Western
immunoblot analysis of ERa expressing clones. The MCF-7 cell
line was used as an ERa-positive control.
doi:10.1371/journal.pone.0031977.g002
Figure 3. pCDNA3-ERa transfectants of MDA-MB-231: Dual-
Luciferase reporter assay for ERa activity. G-418 resistant cell
clones were seeded in 24-well tissue culture plates at 50–70% density in
DMEM supplemented with 5% FCS. Twenty four hours later, cells were
transiently transfected with the pERE-PS2-luc plasmid together with the
pRNL-TK plasmid. Forty eight hours after transfection, cells were lysed
whereby firefly and Renilla luciferase activities were measured and
normalized to the positive control, MCF7.
doi:10.1371/journal.pone.0031977.g003
Figure 4. pCDNA3-ERa transfectants of MDA-MB-231: Respon-
siveness to ligand. MDA-MB-231 derived clones were seeded in
60 mm dishes and grown for 24 hrs under three conditions: DMEM
supplemented with 5% FCS, phenol red-free DMEM supplemented with
5% CSS, and phenol red-free DMEM supplemented with 5% CSS and
2610
28 ME 2. The top panel shows the 66 KDa ERa protein detected
with the anti-hERa antibody. The bottom panel shows the 57 KDa a-
tubulin protein within the same blot after stripping the anti-hERa
antibody and re-probing with the anti-a-tubulin antibody.
doi:10.1371/journal.pone.0031977.g004
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values obtained were normalized to the activity obtained in
MCF7, transfected at the same time point, alongside the clones.
According to Fig. 6, three clones; 231-ERa-7a, 231-ERa-8a, and
231-ERa-17a, maintained an intermediate activity level (40–90%
of MCF7 level) over at least 130 days. Two clones; (231-ERa-3
and 231-ERa-20) displayed relatively low activity, which
eventually (day 130) decayed.
As mentioned above, clones established from the parental
MDA-MB-231 cell line were maintained in culture with DMEM
supplemented with 5% FCS, but also in phenol red-free DMEM
supplemented with 5% CSS. We did not observe any difference in
the cell clones’ stability of receptor activity under the two growth
conditions (data not shown).
Because drug administration efficiency is affected by the
cultured cells’ proliferation rate, we wished to compare the growth
rate of MDA-MB-231 cell clones expressing ERa. As it turned out,
the doubling time of two ERa complemented vs. four ERa non-
complemented (empty) clones was similar (around 21 hours), with
almost identical growth curves (data not shown).
B. Generation and characterization of MDA-MB-231
stable transfectants with ERa expressed from a
bicistronic transcription unit
B1. Transfection & selection. As outlined above, the yield
of MDA-MB-231 stable cell clones expressing ERa, following
stable transfection and G418 selection with the monocistronic
pCDNA3-ERa vector was rather low (12.5%, 5/40). Also, ERa
expression was somewhat unstable over time. Large-scale
experiments with the same vector in the triple negative breast
carcinoma cell line BT549 resulted similarly in only five out of
forty cell clones expressing a ligand responsive hormone receptor
(Moran Gilat, M.Sc. Thesis Tel Aviv University 2006). Moreover,
our other unpublished studies which we performed with MDA-
MB-231 cells transduced with another monocistronic vector,
pCMV-Bam-ERa-Hygro (whose stable selection for Hygromycin
B resistance is driven by the strong HSV TK promoter), resulted
in 48 cell clones, only four of which express the ERa receptor
(Lilach Wallerstein-Shomrony M.Sc. Thesis Tel Aviv University
2006). These inefficient attempts to recover ERa expressing cell
clones had initiated the trial to establish an improved ectopic
expression system using a bicistronic mRNA template for ERa
translation (Fig. 1). The vector consists of a single transcription
unit having the ERa ORF as the upstream cistron, and a
dominant-positive selectable marker (Hygro
R), forming the
downstream cistron, translated from an Internal Ribosome Entry
Site (IRES).
This configuration has the advantage that selection for the
IRES-directed selectable marker gene expression may protect the
transcription unit as a whole, including the upstream ERa ORF.
Thus, this linkage may lead to a high yield of ERa-expressing
clones. Accordingly, MDA-MB-231 parental cells were stably
transfected with the ERa-IRES construct (Fig. 1). Transfection
and selection were performed under minimal estrogen growth
conditions, where phenol red-free DMEM medium supplemented
with 5% CSS was used.
Screening of Hygromycin B resistant clones for ERa expression
was initially performed by Western immunoblot analysis. Fig. 7A
& 7B show the results obtained with the different cell clones.
Surprisingly, all hygromycin B resistant clones (8/8) showed
some level of ERa expression. Upon testing these clones for ERa
activity by the dual luciferase reporter assay, it became evident
that the high frequency of ERa protein expression in the selected
clones is accompanied by ERa activity (Fig. 8). Yet, as also
observed by others, the relationship between Immunoblot
quantification and activity is not always linear, for various
potential reasons such as misfolding of the protein or proteolytic
cleavage of terminal amino acids leading to loss of activity, etc.
Nevertheless, all nine IRES-ERa descendant clones of the
MDA-MB-231 parental cell line showed high ERa-mediated
activation of the reporter gene, amounting from 85% to 841% (!)
of the level displayed by MCF7.
Figure 5. pCDNA3-ERa transfectants of MDA-MB-231: Testing
Response to ERa ligand via the Dual-Luciferase reporter assay.
Clones were plated in 24-well tissue culture plates at 50–70% density
under the three growth conditions mentioned in the legend to Fig. 4.
Twenty four hours later cells were transiently co-transfected with a
p2xERE-pS2-luc plasmid together with a pRNL-TK plasmid. Forty eight
hours after transfection cells were lysed whereby firefly and Renilla
luciferase activities were measured and compared to the positive
control, MCF-7. MDA-MB-231 parental cell-line was used as a negative
control. The presented values were normalized to that of MCF-7 cells
seeded in DMEM supplemented with 5% FCS.
doi:10.1371/journal.pone.0031977.g005
Figure 6. pCDNA3-ERa transfectants of MDA-MB-231: Assaying
stability of ERa trans-activity via the dual luciferase assay. For
each time point, measured in days from the received time of individual
clones covering a 60 mm plate, cells were plated in 24-well tissue
culture plates at 50–70% density, and grown in DMEM supplemented
with 5% FCS. Twenty four hours later, cells were transiently co-
transfected with a p2xERE-pS2-luc plasmid together with a pRNL-TK
plasmid. Forty eight hours after transfection cells were lysed whereby
firefly and Renilla luciferase activities were measured and normalized to
the positive control, MCF-7.
doi:10.1371/journal.pone.0031977.g006
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luciferase assays were performed intermittently over a relatively
long time period (Fig. 9). Cell clones were kept under Hygromycin
B selection, in phenol red-free DMEM medium supplemented
with 5% CSS, in order to minimize potential expression
suppression by the ligand. At each time point of assay, dual
luciferase activity was normalized to the activity obtained in
MCF7, transfected at the same time point, alongside the clones.
Examination of the stability of the ectopically expressed ERa-
IRES clones in MDA-MB-231 over time (Fig. 9), revealed that
three out of four clones still retain appreciable activity (as
compared to that of the reference, MCF7 cells) 155 days after
being initially monitored, amounting to over six months post
transfection with the pERa-IRES vector.
B2. Characterization of the ERa-IRES-Hyg
R containing
transcript. After obtaining a high yield of ERa expressing cell
clones among the hygromycin B resistant transfectants in MDA-
MB-231 (9/9), we set to characterize the ERa-containing hybrid
transcript. A 3.2 kb fused transcript, encoding both cistrons: the
ERa and the hygromycin B resistance selectable marker gene, was
anticipated. Noteworthy, the plasmid sequence contains an intron
situated downstream of the ERa ORF in such a way that splicing
of the intron would result in RT-PCR product shorter by 295 bp
(3.2 kb), compared to the plasmid template PCR product (3.5 Kb).
Lane 8 of Fig. 10A and the second and third lanes from left of
Fig. 10B show that in two representative clones: ERa-IRES-5 and
ERa-IRES-3, the expected 3.2 kb RT-PCR product of the spliced
fused transcript is amplified. In contrast, ERa-2 a cell clone,
described above and created by the monocistronic construct
pCDNA3-ERa and devoid of the Hygromycin selectable marker,
expressed the 1.8 kb ERa RNA product (lane 3 of Fig. 10A). The
ERa-2 cell clone was used as a positive control for the ERa RT-
PCR reaction, since based on prior Northern blot analysis, we
observed that it contained an intact mRNA of the active ERa
protein (data not shown). Thus, we have demonstrated in our
MDA-MB-231 cell clones the presence of a full-length fused ERa-
IRES-Hygro
R transcript, which is also correctly spliced; see in
Fig. 10B for example the PCR product size from pERa-IRES
(3.5 kb) vs. the RT-PCR product from RNA belonging to each of
the two ERa-IRES cell clones (3.2 kb).
B3. Generating stable transfectants with ERa expressed
from a bicistronic transcription unit in MDA-MB-435 &
GILM2 cells. The high yields (9/9) of ERa expressing cell
clones in the TN-derived ERa-deficient breast carcinoma cell line
MDA-MB-231 stands in contrast to previous studies carried out in
our laboratory (and described in part above), as well as those of
others (mentioned before), in which the efficiency of generating
stable ectopic ERa expressing breast carcinoma cells is a
cumbersome and inefficient procedure, resulting in a mere ,5%
valuable clones.
In view of the vast genetic heterogeneity within breast
carcinomas, and the triple-negative breast cancer patients’ group
in particular [21–24], there is demand for generating additional
ectopic ERa producers.
Accordingly, we decided to attempt the bicistronic vector
approach in two more triple-negative breast cancer cell lines:
MDA-MB-435 [15,25], and GILM2 [16]. Both cell lines were
transfected with the pERa-IRES construct as before and selection
with hygromycin B was carried out under minimal estrogen
exposure conditions, as previously outlined.
Initially, we tested the clones for ERa expression by Western
blot analysis. Fig. 11A & 11B show the results obtained with
MDA-MB-435 clones. Importantly, similar to MDA-MB-231,
most of the hygromycin B resistant clones of MDA-MB-435 (13
out of 13) and GILM2 (2 out of 4; data not shown) displayed some
level of ERa expression. We next tested these clones for their ERa
activity, by the dual luciferase reporter assay (Fig. 12). ERa activity
was measured in 12 out of 13 MDA-MB-435 (Fig. 12A) and in two
out of four of the GILM2 ERa-IRES clones (Fig. 12B).
In order to evaluate the stability of ectopic ERa expression over
time of each cell clone, dual-luciferase assays were performed over
a relatively long time period for both cell lines (Fig. 13). Cell clones
were kept under hygromycin B selection and in phenol red-free
DMEM supplemented with 5% CSS for the entire period. They
were exposed to estrogen only at the time of assay.
As it turned out, in the case of MDA-MB-435 derived ERa-
IRES stable transfectants, 11 clones out of 12 retained at least 50%
of their initial ERa activity (data not shown). As compared to the
activity of MCF-7 cells which were assayed alongside the clones, at
each time point, five of the six cell clones had at least 75% of
MCF-7 ERa activity (Fig. 13A). In the case of the two GILM2
Figure 7. pERa-IRES MDA-MB-231 transfectants: ERa expres-
sion via Western immunoblot analysis. A. MDA-MB-231 clones
selected for Hygromycin B resistance were lysed and ERa expression
was tested by Western immunoblot analysis. ERa positive MCF-7 cell
line was used as a positive control. MDA-MB-231 parental cell-line
represented the negative control. B. Representation of ERa steady state
expression values. The values of ERa expression were normalized to
tubulin expression, with MCF7 value being one unit.
doi:10.1371/journal.pone.0031977.g007
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retention of their initial ERa activity (Fig. 13B).
Discussion
This project was aimed at establishing an efficient method for
ERa complementation in various ERa-deficient cell lines. The
generation of these complemented clones served as a counterpart
control ingredient for synthetic lethality screening systems in ERa-
deficient TN breast carcinoma cell lines.
Studies performed by others [17,18], together with unpublished
experiments performed in our laboratory in breast cancer BT549
cells and MDA-MB-231 cells (mentioned in Section B.1) have
shown that the yield of cell transfectants expressing appreciable
levels of ectopically mono-cistronic transduced ERa is very low (5–
12.5%). Our attempts to generate such MDA-MB-231 stable
transfectants under minimal exposure to the ERa ligand did not
improve this low efficiency (Figs. 2–6). Moreover, stable ERa
expression in the MDA-MB-231 cell line transfectants lasted for
130 days in only three out of the initial five ‘‘stable’’ clones
monitored for prolonged periods (Fig. 6). We therefore decided to
try setting up a modified system in which the fraction of ERa
expressing cell clones would be higher and the expression perhaps
more stable.
Based on the discovery of the EMCV IRES element by E.
Wimmer’s laboratory, researchers have started using IRES-
containing bicistronic mammalian vectors to co-express multiple
genes [11,12,26,27]. Following that line, we chose the pIREShyg3
mammalian bicistronic expression vector. This vector is equipped
with multiple cloning sites downstream of the strong cap-
dependent CMV immediate early promoter and upstream of an
intron fused to the IRES element which directs the translation of
the dominant selectable marker-Hygromycin B resistance. Despite
weaker translation from the downstream IRES element, the
Hygromycin B resistance gene can be easily selected for. We
cloned the ERa ORF into this bicistronic vector and then
transfected it into the MDA-MB-231 breast carcinoma cell line.
Maintaining the cells under phenol red-free DMEM supplemented
with 5% CSS while selecting for Hygromycin B resistance, led to
the isolation of nine clones. The ERa producing clones were
identified by Western immunoblot analysis. All Hygromycin B
resistant cell clones expressed the correct size ERa protein (Fig. 7).
When assayed, the ERa protein turned out to be functionally
active (Fig. 8). Importantly, nine out of the nine clones had high
levels of ERa expression. Evidently, the selection for expression of
the downstream Hygro
R gene had a protecting effect on the
upstream ERa gene expression from the same (bicistronic)
transcription unit.
The mRNAs of the ERa producing clones were tested in an
RT-PCR assay, verifying the integrity of the bicistronic mRNA
(Fig. 10). Yet, with regard to MDA-MB-231 parental cells,
although we were able to obtain cell clones such as ERa-IRES-3,
which retained significant activity over a period of at least 155
days, most of MDA-MB-231 IRES-ERa descendents had
Figure 8. pERa-IRES MDA-MB-231 transfectants: Dual-Luciferase reporter assay for ERa activity. Technical details as in the legend to
Fig. 6.
doi:10.1371/journal.pone.0031977.g008
Figure 9. pERa-IRES MDA-MB-231 transfectants: ERa activity
over time. Technical details as in the legend to Fig. 6.
doi:10.1371/journal.pone.0031977.g009
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intermediate level of expression, alongside plentiful clones was
sufficient to complete any screen or study required.
Following MDA-MB-231 cells, we attempted usage of the
pIRES-ERa vector in other breast cancer cell lines: MDA-MB-
435, and GILM2. We received high initial yields of ERa
expression; 12 out of 13 clones for MDA-MB-435, and 2 out of
4 for GILM2 (Figs. 11 & 12). Most of these cell clones retained
high activity for at least 98 days (Figs. 13a & 13b).
Noteworthy, usage of the Hygro
R selectable marker gene driven
by the relatively strong promoter HSV TK, such as in the mono-
cistronic ERa expressing vector pCMV-Bam-ERa-Hygro, led to
only 3–4 stable MDA-MB-231 cell clones out of forty eight which
express the ERa receptor (Lilach Wallerstein-Shomrony M.Sc.
Thesis Tel Aviv University 2006). So the difference in the yield of
stable ERa expressing cell clones between the bicistronic vector
and the mono-cistronic pCDNA3-ERa cannot be due to the usage
of a different selectable marker (Hygromycin
R vs. neo
R)o ra
weaker promoter driving the selectable gene (CMV vs. SV40
early), respectively.
The proven ability of the bicistronic vector to generate multiple
ERa expressing clones at very high yields, which for the most part
retain stable expression upon further propagation, is the major
Figure 10. Characterization of ectopically expressed RNAs by
long range RT-PCR. MDA-MB-231 parental cell line (231-parental), its
pcDNA3-ERa stable transfectant (ERa-2), and its ERa-IRES stable
transfectants (ERa-IRES-5 and ERa-IRES-3) were analyzed for expression
of ERa–harboring transcript (1.8 kb), Hygromycin B resistance gene-
containing transcript (1.0 kb), and ERa-IRES-Hygro
R fused transcript
(3.2 kb), by RT followed by long range PCR amplification. pERa-IRES
DNA served as a PCR positive control for the ERa cDNA primers (1.8 kb),
the Hygromycin B resistance gene ORF primers (1.0 kb), and the 59
sense ERa primer plus 39 antisense Hygro
R fused ORFs primers (3.5 kb).
A First four lanes from left contain the ERa cDNA primers; lanes 5–8 the
59 sense ERa primer together with the 39 antisense Hygro
R gene primer.
B. The 59 sense ERa primer together with the 39 antisense Hygro
R gene
primer. C. Lanes 1 and 2 from left, the ERa primers. Lanes 3 and 4 the
Hygro
R gene primers. Primer sequences are detailed in the ‘‘Methods’’
section.
doi:10.1371/journal.pone.0031977.g010
Figure 11. pERa-IRES MDA-MB-435 transfectants: Western
immunoblot analysis of ERa protein. A. MDA-MB-435 cell clones
selected for Hygromycin B resistance were lysed and ERa expression
was tested by Western immunoblot analysis. ERa positive MCF-7 cell
line was used as a positive control. MDA-MB-435 parental cell-line
represented the negative control. B. Representation of ERa steady state
expression values. The values of ERa expression were normalized to a
tubulin expression in the cells.
doi:10.1371/journal.pone.0031977.g011
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encountering hardships in other ectopic gene expression systems,
to adopt the usage of such bi- or multi-cistronic vectors.
Using the cell systems generated in MDA-MB-231, MDA-MB-
435 and GIML2, we are now focusing our attempts on genetic
synthetic lethality screenings [7]. These screenings entail a group of
100 human antiapoptotic/survival genes (known to be expressed in
human breast cancers), and thereby promoting tumor growth and
survival, as well as a lentiviral pool of shRNAs expressing clones
targeted against all known human coding RNAs [7].
Figure 12. pERa-IRES MDA-MB-435 (A) & GILM2 transfectants (B): Dual-Luciferase reporter assay screening for ERa activity. Technical
details as in the legend to Fig. 6.
doi:10.1371/journal.pone.0031977.g012
Figure 13. pERa-IRES MDA-MB-435 (A) & GILM2 transfectants (B): ERa activity over time. Technical details as in the legend to Fig. 6. ERa
values were normalized to the values obtained at each time point with MCF-7 cells, taken as the 100%.
doi:10.1371/journal.pone.0031977.g013
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